uniQure N.V. Lessee, Operating Lease, Liability, to be Paid, after Year Five
uniQure N.V. (QURE) had Lessee, Operating Lease, Liability, to be Paid, after Year Five of $1.82 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive · last filed 2026-03-02
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $1.82M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $3.49M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $8.39M.
- 2022-12-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $17.00M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, after Year Five |
|---|---|
| 2025-12-31 | $1.82M 10-K · filed 2026-03-02 |
| 2024-12-31 | $3.49M 10-K · filed 2025-02-27 |
| 2023-12-31 | $8.39M 10-K · filed 2024-02-28 |
| 2022-12-31 | $17.00M 10-K · filed 2023-02-27 |
| 2021-12-31 | $21.42M 10-K · filed 2022-02-25 |
| 2020-12-31 | $28.52M 10-K · filed 2021-03-01 |
| 2020-06-30 | $33.84M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $33.58M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $33.83M 10-K · filed 2020-03-02 |
| 2019-09-30 | $39.47M 10-Q · filed 2019-10-28 |
| 2019-06-30 | $40.23M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $30.89M 10-Q · filed 2019-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |